Halo is a minor position for me. It's a technology that allows for a switch from infused drugs to injectable. Roche has partnered with them for 4 antibody switches with options for 10 more. The 4 are all early in the clinic but could move rapidly if Roche is motivated. Baxter is working on switching an infused plasma drug ($1b+) to injectable and that's in phase 3 in a very low risk filing strategy.
Why its not a big position for me is i'm not as sold on halo's internal ideas such as rapid acting insulin which they seem to be placing their biggest bet.
Market Data 
Markets 
AI
